Previous Article | Next Article ![]()
Molecular and Cellular Biology, March 2008, p. 1489-1502, Vol. 28, No. 5
0270-7306/08/$08.00+0 doi:10.1128/MCB.01090-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Department of Medicine,1 Program in Genetics,2 Department of Pharmacological Sciences,3 Department of Pathology, State University of New York at Stony Brook, Stony Brook, New York 117944
Received 19 June 2007/ Returned for modification 24 July 2007/ Accepted 19 December 2007
|
|
|---|
|
|
|---|
β-Catenin is a convergence point for Wnt and cellular adhesion pathways, functioning as a structural adaptor protein linking type I cadherins to the actin cytoskeleton and as a transcriptional cofactor in the Wnt pathway when in complex with T-cell factor/lymphoid enhancer factor (39). Normally, the majority of β-catenin is associated with E-cadherin at cell-cell junctions, and β-catenin is maintained at low cytoplasmic levels. In the absence of Wnt signaling, cytoplasmic β-catenin is bound to its destruction complex of Axin, adenomatosis polyposis coli, and glycogen synthase 3β kinase (GSK-3β), where it is targeted for ubiquitination and degradation in the 26S proteosome. Upon the activation of Wnt/β-catenin pathways, the β-catenin destruction complex dissociates and β-catenin escapes phosphorylation by GSK-3β and translocates to the nucleus, where it activates an array of target genes and cell cycle regulators such as c-myc and cyclin D1 (5, 29). β-catenin deficiency in mice causes lethality at embryonic day 7 (20), while liver-specific disruption of murine Apc (encoding adenomatosis polyposis coli) results in β-catenin signaling activation and the development of HCC (12). In contrast, hepatocyte-restricted overexpression of an oncogenic β-catenin transgene causes hepatomegaly without HCC formation (9). Similarly, the adenovirus-mediated expression of a dominant stable β-catenin mutant failed to cause neoplastic liver foci, suggesting that in contrast to adenomatosis polyposis coli, the activation of the Wnt signaling pathway by stabilized β-catenin is insufficient for HCC development, further suggesting that additional genetic or epigenetic changes are involved (21).
We now provide evidence that IQGAP2 functions as a critical component of a broader IQGAP1-IQGAP2-β-catenin-E-cadherin scaffold and that the loss of IQGAP2 expression by the targeted disruption of the murine Iqgap2 gene leads to the development of HCC. Of equal importance, mice deficient in both Iqgap1 and Iqgap2 genes (Iqgap1–/– Iqgap2–/–) displayed relative protection against HCC and corrected long-term survival rates relative to those of Iqgap2–/– mice, suggesting that IQGAP1 and IQGAP2 retain functionally divergent roles in hepatocellular carcinogenesis. IQGAPs are conserved homologues of an extended family of proteins found in yeast (Saccharomyces cerevisiae) and amoebae (Dictyostelium discoideum), studied in mammalian systems largely as scaffolding proteins with the capacity of integrating intracellular signals with cytoskeletal membrane events (1, 7, 32, 42). In mammals, two homologous IQGAPs (IQGAP1 and IQGAP2) have been characterized previously (8, 22, 27, 34), although a third (IQGAP3) was recently identified on the basis of homology search and implicated in axonal elongation in PC12 cells and rat hippocampal neurons (50). IQGAPs bind F-actin through the calponin homology domain (10) and interact with multiple calmodulin molecules in a predominantly Ca2+-independent fashion through repetitive IQ motifs (IQXXXRGXXR) (8) and with Rho GTPases cdc42 and rac1 by means of a C-terminal RasGAP-related domain (GRD) (8). While IQGAP1 is known to capture microtubules through its association with cytoplasmic linker protein 170 (CLIP-170) (17) and to modulate cadherin-based adhesion by acting as a competitive inhibitor of β-catenin-cadherin complex formation (6, 28), the physiological significance of these biochemical interactions remains unknown. These data establish the first identified pathological consequence of IQGAP2 deficiency and provide a novel function for Iqgap2 as a tumor suppressor gene coupled to the activation of the Wnt/β-catenin signaling pathway.
|
|
|---|
150-kb bacterial artificial chromosome clone derived from murine chromosome 13 and encompassing exons 7 to 34 of the Iqgap2 gene was isolated as previously described (14). The targeting vector was constructed by the insertion of an 8.5-kb genomic fragment containing Iqgap2 exons 15 to 17 into the BamHI site of plasmid pMJK-KO (available from Thomas Rosenquist, State University of New York [SUNY]—Stony Brook), upstream from the phosphoglycerate kinase promoter-neomycin (PGK-Neo) reporter cassette. An 8-kb Iqgap2 genomic fragment encompassing exon 31 was cloned into the XhoI site downstream of the PGK-Neo cassette. The targeting vector also contained a thymidine kinase gene (PGK-tk) as a second selection marker (see Fig. 1A). The linearized targeting vector was introduced into 129J1 embryonic stem (ES) cells by electroporation, and the Iqgap2 null allele was generated by homologous recombination using dual selection (33). Genomic DNA from individual ES clones was screened by Southern analysis using ApaI-digested DNA and a 32P-radiolabeled, PCR-generated 500-bp fragment as a probe (forward, 5'-GCTGGCAGTGGGGAGCACAGTGCA-3'; reverse, 5'-AGGGCAGGAAAGGCAGCAGCACTT-3'). ES clone no. 57 was used for microinjections into C57BL/6 blastocysts to generate chimeric mice (33) and bred into 129J1 and C57BL/6 backgrounds for at least eight generations prior to further studies. All functional studies were completed using 129J1 mice. F1 progeny of the chimeric mice were initially genotyped by Southern blot analysis (as outlined above) using tail DNA. Genotyping of subsequent progeny was completed by PCR. Oligonucleotide pair P3/P4 (P3, 5'-AAGGCATGATTCATTCACCTGAGA-3'; P4, 5'-AGGGCAGGAAAGGCAGCAGCACTT-3') was used for the detection of the wild-type allele, and N2/N3 (N2, 5'-GTCAAGAAGGCGATAGAAGG-3'; N3, 5'-TTGAACAAGATGGATTGCACGCA-3') was used for the null allele. The 35-cycle PCR included a denaturation step at 94°C for 1 min and 15 s, a 2-min annealing step at 55°C, and a 3-min primer extension step at 72°C.
![]() View larger version (49K): [in a new window] |
FIG. 1. Generation and characterization of Iqgap2–/– mice. (A) Schema depicting the targeting construct and the Iqgap2 wild-type and null alleles, resulting in the replacement of an 36-kb genomic fragment (corresponding to amino acid residues Ala705 to Lys1306) with the PGK-Neo cassette. The deleted fragment encompasses a portion of the IQ2 (Gln696-to-Gly725), IQ3 (Asn726-to-Asp755), and IQ4 (His756-to-Pro785) domains and the GRD (Gln891 to Val1189) (8). Selected numbered exons are depicted by rectangles, and the relative positions of oligonucleotides and the 32P-radiolabeled probe used for allele identification are shown. A, ApaI; B, BamHI; X, XbaI. (B and C) Southern blot analysis was performed using 10 µg of ApaI-digested genomic DNA isolated from various ES clones (B) or Iqgap2–/– (–/–), Iqgap2+/– (+/–), or wild-type (+/+) mice (C) specifically generated from ES clone no. 57, and DNA was probed with the 32P-radiolabeled 500-bp genomic fragment depicted in panel A. The 4-kb wild-type and 12-kb mutant alleles are evident. (D) qRT-PCR was completed using total RNA isolated from livers of 2-month-old wild-type, Iqgap1–/–, or Iqgap2–/– mice and primers specific for the β-actin gene, Iqgap1, Iqgap2, and Par3 (known to be encompassed within the Iqgap2 gene [14]). (E) Total protein lysates (10 µg per lane) isolated from organs of 2-month-old Iqgap2–/– (–/–) or Iqgap2+/– (+/–) mice or wild-type (+/+) littermate controls were size fractionated by 4 to 15% SDS-PAGE, and IQGAP1 and IQGAP2 expression was assessed by immunoblotting. Note the absence of IQGAP2 in all Iqgap2–/– organs, with a modest reciprocal increase in IQGAP1 in Iqgap2–/– livers only.
|
Molecular genetic analyses. The integrity of liver mitochondrial DNA from Iqgap2–/– mice was assessed by Southern blotting using a 2-kb EcoRI fragment of a mouse mitochondrial genome as a probe (43). Total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA). RNA integrity was established using an Agilent 2100 bioanalyzer.
Quantitative reverse transcription-PCR (qRT-PCR) was performed using fluorescence-based real-time PCR technology (19); in brief, 5 µg of total RNA from murine livers was used for first-strand cDNA synthesis with random hexamer primers (Invitrogen, Carlsbad, CA). Total RNA in 7 µl of H2O was mixed with 5 µl of hexamer primers (100 ng/µl), and the mixture was heated to 85°C for 3 min and placed on ice. The reaction mix was prepared separately according to the Invitrogen protocol and contained 4 µl of 5x first-strand buffer, 2 µl of 0.1 M dithiothreitol, and 1 µl of a mix of deoxynucleoside triphosphates (15 mM each). RNA with primers was then added to the reaction mix, the mixture was incubated at 42°C for 3 min, and the reverse transcription was started by the addition of 1 µl of SuperScript II reverse transcriptase (200 U/µl; Invitrogen [catalog no. 18064]). The reverse transcription reaction was carried out at 42°C for 2 h and stopped by incubation of the reaction mixture at 85°C for 10 min.
The following PCR step was performed in a 96-well plate using an Opticon-I PCR machine (Bio-Rad). The reverse transcription reaction mixture was diluted up to 1:15 and equally divided among primer pairs for each target gene (Table 1). Oligonucleotide primer pairs for each target gene were generated using Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and were designed to amplify PCR products of 200 ± 1 bp at the same annealing temperatures. The plate was heated at 95°C for 15 min and subjected to a 40-cycle PCR (94°C for 30 s, 55°C for 30 s, and 72°C for 1 min and fluorescence reading for 10 s). Melting curves were measured for every well of the plate at temperatures from 65 to 95°C, with a reading interval of 0.2°C and 5 s of holding between the readings. mRNA levels were quantified by monitoring the real-time fluorimetric intensity of SYBR green I (Invitrogen). Known amounts of DNA were used as standards to generate a calibration curve covering a range from 1 to 10–6 ng of a target per well. The relative mRNA abundance was determined from triplicate assays performed in parallel for each primer pair and calculated using the comparative threshold cycle number (23), and results were normalized to the amount for cellular β-actin mRNA, all as previously described (18).
|
View this table: [in a new window] |
TABLE 1. Oligonucleotide primers for qRT-PCR
|
Biochemical determinations (for hepatic transferases, bilirubin, and alkaline phosphatase) were completed using sera isolated from retroorbital blood samples and quantified using a MODULAR PP serum work area analyzer (Roche Diagnostics, Indianapolis, IN). Automated blood counts were obtained on a Coulter counter specifically gated to detect murine blood cells, and blood smears were subjected to Wright-Giemsa stain.
Hepatocyte TUNEL and mitochondrial assays. The quantification of apoptotic hepatocytes was completed using terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) staining (31). Briefly, liver sections were deparaffinized in xylene, rehydrated in decreasing alcohol concentrations (from 100 to 0%), and digested with 20 µg/ml of proteinase K for 10 min at 25°C, and the digestion was subsequently quenched by incubation with 3% hydrogen peroxide in phosphate-buffered saline for 10 min at 25°C. Washed sections were then incubated for 60 min at 37°C with terminal deoxynucleotidyltransferase enzyme for dUTP-biotin nick end labeling (Chemicon, Temecula, CA), after which they were incubated for 1 h at 25°C with the digoxigenin-conjugated anti-dUTP antibody. Detection was completed using 3,3'-diaminobenzidine as the substrate. Sections were counterstained with 0.5% methyl green. Apoptotic cells (among 1,000 cells per section) were scored and quantified in a blinded fashion by two investigators, and the results were expressed as the mean ± the standard error of the mean (SEM) for each age group studied.
Mitochondria were isolated from individual livers after isotonic homogenization in an ice-cold buffer containing 0.25 M sucrose, 10 mM HEPES buffer, pH 7.4, and 1 mM EGTA. The mitochondrial fraction was obtained by differential centrifugation at 4°C (48), and the protein content was measured by a bicinchoninic acid assay (Pierce, Rockford, IL). The integrity and functional capacity of mitochondria were assessed by tetramethylrhodamine ethyl ester loading (50 mM for 10 min at 25°C) and FACScan analysis using logarithmic-gain settings for light scattering and fluorescence (Becton Dickenson, Mountain View, CA). For all studies, 10,000 gated events were acquired.
Immunodetection and immunoprecipitation studies. Immunohistochemistry analysis of paraffin-embedded liver sections was performed essentially as described previously (25) using mouse monoclonal antibodies specific for β-catenin (1:50; clone 14, BD Biosciences, San Jose, CA), E-cadherin (1:50; BD Biosciences), IQGAP1 (1:15; BD Biosciences), and IQGAP2 (1:50; Upstate Biotechnology/Millipore, Billerica, MA). The detection of primary antibody was carried out using a biotinylated mouse-specific secondary antibody (1:100), streptavidin peroxidase (Rockland Immunochemicals for Research, Gilbertsville, PA), and 3,3'-diaminobenzidine as the substrate.
Protein lysates from various organs were prepared as previously described (42). Lysates were centrifuged at 600 x g for 10 min at 4°C, and protein supernatants were quantified by a bicinchoninic acid assay prior to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using 4 to 15% gradient gels (Bio-Rad Laboratories, Hercules, CA). Immunoblot analysis was completed as previously described (2). Primary antibodies, all mouse monoclonal antibodies, were as follows: IQGAP1 (1:1,000; BD Biosciences), IQGAP2 (1:1,000; Upstate Biotechnology/Millipore), actin (1:1,000; Chemicon, Temecula, CA), glyceraldehyde-3-phosphate dehydrogenase (1:1,000; Upstate Biotechnology/Millipore), cytochrome c (1:1,000; Cell Signaling Technology, Danvers, MA), complex I and II (both 1:200; Molecular Probes, Eugene, OR), prohibitin (1:500; Lab Vision Co., Fremont, CA), β-catenin (1:1,000; clone 14; BD Biosciences), active β-catenin (anti-ABC; 1:1,000; clone 8E7; Upstate Biotechnology/Millipore), E-cadherin (1:1,000; BD Biosciences), and cyclin D1 (1:400; Upstate Biotechnology/Millipore). Relative protein abundance was determined by densitometric analysis using Gel-Pro Analyzer software (version 3.0; Media Cybergenetics, Silver Spring, MD).
Immunoprecipitation experiments were completed using freshly isolated murine livers essentially as described previously (42). In brief, intact livers were homogenized in 25 mM HEPES-0.15 M NaCl buffer, pH 7.45, supplemented with 0.1% Triton X-100 and standard protease inhibitors. After centrifugation at 10,000 x g for 15 min at 4°C, 5 to 20 mg of whole-cell lysate was precleared in a 1-ml volume by using 50 µl of protein G agarose (25-µl bed volume; Roche Diagnostics GmbH, Mannheim, Germany) for up to 4 h at 4°C. After centrifugation at 12,000 x g for 20 s, supernatants were incubated with 5 µg of protein G agarose-conjugated antibodies overnight at 4°C. Pellets were then collected by centrifugation (12,000 x g for 20 s) and washed three times with lysis buffer prior to immunoblotting as outlined above.
Alternatively, immunoprecipitation experiments were carried out with COS1 lysates. COS1 cells were grown in Dulbecco minimal essential medium supplemented with 10% fetal bovine serum, 100 U/ml of penicillin, and 100 µg/ml of streptomycin sulfate. Transient transfections with full-length human IQGAP1 cDNA (kindly provided by David Sacks, Harvard Medical School) (24) and IQGAP2 cDNA (a gift from Andre Bernards, Harvard Medical School) (8) were completed using Fugene reagent (Roche Diagnostics). Transfection with EGFP-C1 plasmid (Clontech Laboratories, Mountain View, CA) served as a control; 24 h posttransfection, cells were washed and solubilized in a buffer containing 25 mM HEPES-0.15 M NaCl buffer, pH 7.45, supplemented with 0.1% Triton X-100 and standard protease inhibitors. Lysates were subsequently used for immunoprecipitation studies as outlined above.
Statistical analyses.
Kaplan-Meier survival curves and age-dependent HCC incidence data were generated using SPSS software (Statistical Package for the Social Sciences, version 14.0). For all analyses, differences in means between groups were analyzed by a
2 test or two-tailed Student's t test using a P value of <0.05 as a measure of statistical significance.
|
|
|---|
Iqgap2–/– mice display age-dependent hepatocellular apoptosis. The initial survey of organs from 6-week-old Iqgap2–/– mice demonstrated no histological defects in any of the tissues studied; similarly, animals were fertile and maintained normal body weights. More-detailed hematological and biochemical studies of mice from distinct age groups (1, 4, and 8 months old) revealed normal hemograms, although Iqgap2–/– mice demonstrated an age-dependent increase in levels of distinct hepatocyte-derived aminotransferases in sera. Total bilirubin levels remained normal in mice up to 8 months of age, and enzymatic abnormality at this age was restricted to elevations of aspartate aminotransferase (AST) (Fig. 2A), to the exclusion of a rise in alanine aminotransferase (data not shown). A nonstatistically significant rise in AST was evident at 4 months, with clear differences in 8-month-old Iqgap2–/– mice (P = 0.04) compared to wild-type littermates. The AST was most likely hepatic (nonmuscular) in origin, since corresponding serum creatine phosphokinase levels remained normal and values for the two groups were statistically indistinguishable (53.6 ± 6.3 U/liter in wild-type mice versus 72.4 ± 20.59 U/liter in Iqgap2–/– mice). Similarly, the extensive organ survey failed to identify histologic defects in any nonhepatic sources. Although this pattern evident in Iqgap2–/– mice is typical of human alcoholic liver disease (i.e., disproportional elevations of AST compared to alanine aminotransferase), hepatic nonesterified fatty acid and triglyceride levels were normal (data not shown).
![]() View larger version (98K): [in a new window] |
FIG. 2. Age-dependent hepatopathy and mitochondrial damage in Iqgap2–/– mice. (A) Sera from mice in three age groups (1, 4, and 8 months old; n = 10 mice per age group) were analyzed for the quantification of AST. (B) Liver sections (n = 3 per age group) were analyzed for apoptotic cells by TUNEL staining. Results shown in panels A and B are means ± SEM; statistically significant P values are shown. (C and D) Transmission electron micrographs from livers and skeletal muscles of 12-month-old Iqgap2–/– mice (low and high magnifications) (C) or wild-type mice (high magnification) (D) demonstrate an edematous mitochondrial matrix with collapsed cristae (solid arrows) restricted to Iqgap2–/– mitochondria; hollow arrows indicate normal cristae. Note the normal architecture of mitochondria from skeletal muscles of both genotypes. Structural defects are representative of those seen in 8- and 12-month-old mice (n = 3 per group), with comparable but less-extensive defects seen in 4-month-old Iqgap2–/– mice. Size bars represent 2 µm (magnification, x4,800 [C, top left panel]), 500 nm (magnification, x18,500 [C, top right panel]), and 200 nm (magnification, x49,000 [C, bottom panels, and D]). The white box denotes an Iqgap2–/– mitochondrion shown magnified at x49,000 in the image below.
|
Structural mitochondrial abnormalities in Iqgap2–/– hepatocytes. The age-related onset of the apoptotic phenotype evident in Iqgap2–/– hepatocytes is characteristic of many mitochondrial diseases and is postulated to result from the senescent decline in oxidative phosphorylation seen in postmitotic tissues such as liver (52). An ultrastructural review of hepatocytes from Iqgap2–/– mice (ages 1, 4, 8, and 12 months; n = 3 per age group) displayed distinct age-dependent abnormalities restricted to mitochondria (Fig. 2C and D). These defects were not present in any age-matched wild-type mice examined (n = 8), were more pronounced with age, and were restricted to the liver (to the exclusion of skeletal muscle). Furthermore, there was no evidence for associated abnormalities of mitochondrial number, as assessed by quantitative PCR and genomic blotting of mitochondrial DNA (data not shown), qRT-PCR analysis of mitochondrial RNA transcripts, or immunoblot analysis of key mitochondrial proteins (Fig. 3A and B) (35). Finally, the functional competence of the mitochondrial permeability transition pore (mtPTP; the complex regulating cytochrome c release as a primary apoptotic signal [13]) was found to be normal, as assessed by comparable dose-response sensitivities to calcium (the fundamental mtPTP activator) and valinomycin (a potassium-specific inducer of the mtPTP [45]) (Fig. 3C and D). Collectively, these data suggested that IQGAP2 deficiency caused hepatocellular apoptosis through a mitochondrial pathway unrelated to a concomitant intrinsic defect of mitochondrial function.
![]() View larger version (19K): [in a new window] |
FIG. 3. Mitochondrial characterization of Iqgap2–/– mice. (A) qRT-PCR was completed using total liver RNA from 12-month-old Iqgap2–/– mice or age-matched wild-type controls. 16S, 16S subunit rRNA; COX, cytochrome c oxidase subunit 1; Cyt b, cytochrome b. The bar graphs show means ± standard deviations of results from triplicate wells, normalized using β-actin; the results shown represent one complete set of experiments, repeated on two occasions. (B) Immunoblot analysis of liver and skeletal muscle lysates (10 µg/lane) from wild-type (+/+) and Iqgap2–/– (–/–) mice using antibodies specific to complex I, complex II, prohibitin, and cytochrome c. (C and D) Flow cytometry analysis of mitochondria (equivalent to 300 µg of protein/sample) isolated from hepatocytes from 8-month-old Iqgap2–/– or age-matched wild-type mice, loaded with tetramethylrhodamine ethyl ester, and incubated with the specified concentrations of valinomycin (C) or CaCl2 (D). For all experiments, the percentage of dye retention was determined from the geometric mean for 10,000 events, with 100% representing the baseline fluorescence of intact mitochondria. Results are the means ± SEM from two distinct experiments.
|
![]() View larger version (96K): [in a new window] |
FIG. 4. Development of HCC in Iqgap2–/– mice. (A) Gross morphological evidence of HCC in the liver of a 2-year-old Iqgap2–/– mouse compared to the liver of an age-matched wild-type control; asterisks denote multiple large, vascularized nodules. The scale bars correspond to 1 cm. (B) Representative hematoxylin- and eosin-stained sections from wild-type or Iqgap2–/– livers demonstrating HCC in Iqgap2–/– mice. The spiked line (right upper panel) delineates the border between normal (N) and tumor (T) tissue. Scale bars correspond to 150 µm (top panels) and 50 µm (bottom panels). (C) Representative reticulin-stained livers from wild-type and Iqgap2–/– mice showing HCC. Note the discontinuous patterns of reticulin fibers in the HCC liver tissue. Scale bars correspond to 200 µm.
|
![]() View larger version (61K): [in a new window] |
FIG. 5. Molecular analysis of HCC in Iqgap2–/– mice. (A) Immunohistochemical detection of IQGAP1, β-catenin, and E-cadherin in livers from 4-month-old wild-type or Iqgap2–/– mice without HCC or 2-year-old Iqgap2–/– mice with HCC. Note the loss of E-cadherin from cell membranes, along with the enhanced cytoplasmic expression and translocation of both IQGAP1 and β-catenin, occurring only with HCC. Scale bars correspond to 50 µm. (B) Immunoblot analysis was completed using an anti-β-catenin monoclonal antibody and liver lysates (10 µg/lane) from mice (2 years old) with HCC or age-matched controls; the arrow indicates the 92-kDa β-catenin band, with clear evidence for truncated β-catenin mutant forms in the case of HCC. (C) Immunoblot (10 µg of lysate/lane) demonstrating the presence of active (dephosphorylated) β-catenin mutant forms in HCC liver tissue. Results for livers from two 4-month-old wild-type (WT) and Iqgap2–/– (–/–) mice are also shown. Cell lysate from the A431 cell line (Upstate Biotechnology/Millipore) was used as a positive control. (D) Immunoblot analysis (10 µg of lysate/lane) to assess E-cadherin, cyclin D1, and IQGAP1 expression in Iqgap2–/– liver lobes without HCC or affected by HCC; paired normal (N) and tumor (T) samples were collected from the same animals. (E) Immunoblot densitometric analysis of E-cadherin, cyclin D1, and IQGAP1 expression was conducted using liver lysates (10 µg/lane) from lobes affected by HCC (n = 4), those of 4- and 12-month-old Iqgap2–/– mice without HCC (n = 3), and those of 4-month-old wild-type mice (n = 2). Data are presented as mean ratios ± standard deviations of the expression of individual proteins relative to that of proteins in the wild-type samples. (F) IQGAP1 expression was assessed by immunoblotting of liver lysates (10 µg/lane) from wild-type (WT) and Iqgap2–/– (–/–) mice of various ages (6 weeks and 4, 12, and 24 months). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-specific antibody served as a control for the loading of equal quantities. A representative immunoblot is shown. (G) Immunoblot densitometric analysis of hepatic IQGAP1 expression in wild-type and Iqgap2–/– mice of various ages. Data are presented as means ± SEM of the integrated optical densities of bands. n = 3 for each age group.
|
12% of that in wild-type livers, consistent with immunohistochemistry data. Noteworthily, more-extensive studies demonstrated enhanced (
2.5-fold) cyclin D1 and IQGAP1 expression in the livers of younger Iqgap2–/– mice without HCC, establishing that IQGAP1 upregulation and cyclin D1 activation predated histological evidence for HCC development (Fig. 5E). To assess the timing of IQGAP1 upregulation in greater detail, liver lysates from wild-type and Iqgap2–/– mice ranging in age from 1.5 to 24 months were analyzed for IQGAP1 protein expression. As shown in Fig. 5F and G, IQGAP1 was overexpressed in all Iqgap2–/– samples compared to expression in wild-type samples, irrespective of the age of the mice, and this overexpression thus clearly predated the onset of HCC development. Therefore, while IQGAP1 is evidently upregulated in Iqgap2–/– mice with HCC, the reciprocal induction appears to be present early on (by 16 weeks of age) and is sustained with age. Remarkably, no change in IQGAP1 expression was observed in other organs known to express IQGAP1, including hearts, lungs, kidneys, and spleens, from Iqgap2–/– 4- and 12-month-old mice (data not shown). A multiprotein β-catenin-E-cadherin-IQGAP1-IQGAP2 scaffold exists in hepatocytes. To further probe the relationships between IQGAP1, IQGAP2, β-catenin, and E-cadherin, a series of immunoprecipitation experiments were conducted using whole-liver lysates from Iqgap1–/–, Iqgap2–/–, and wild-type mice. As shown in Fig. 6A, all these proteins are clearly associated as components of a multiprotein scaffolding complex present in normal hepatocytes, as established using a β-catenin pull-down assay. In contrast, we saw no evidence for specific interaction between E-cadherin and IQGAP2 in either E-cadherin- or IQGAP2-specific immunoprecipitations (data not shown). Interestingly, in the β-catenin pull-down assays of Iqgap1–/– and Iqgap2–/– livers, β-catenin was associated with less IQGAP2 and IQGAP1, respectively, than in assays of wild-type livers, suggesting that IQGAP1 and IQGAP2 were functionally cooperative within this complex. Using normal hepatocytes, however, neither IQGAP1- nor IQGAP2-specific pull-down assays coprecipitated the corresponding homologous protein (data not shown). Transient transfections of COS1 cells (which endogenously express IQGAP1) were subsequently used as an in vitro model system to specifically address the existence of putative IQGAP1-IQGAP2 heterodimers. As evident in Fig. 6B, we were unable to pull down IQGAP1 or IQGAP2 by using reciprocal immunoprecipitations. Thus, while IQGAP1 and IQGAP2 are normally found as components of a broader quarternary scaffolding complex in hepatocytes, there appears to be no evidence that their presence within this scaffold occurs via direct (heterodimeric) interactions.
![]() View larger version (43K): [in a new window] |
FIG. 6. Molecular interactions involving IQGAPs, β-catenin, and E-cadherin. (A) Immunoprecipitations were completed using liver lysates (20 mg of total protein per sample) from 12-month-old wild-type (WT), Iqgap1–/–, or Iqgap2–/– mice and a protein G agarose-conjugated anti-β-catenin antibody (5 µg per sample). Complexes were fractionated by 4 to 15% gradient SDS-PAGE and immunodetected using antibodies specific to IQGAP1, IQGAP2, β-catenin, and E-cadherin. Results represent one complete set of experiments reproduced on two different occasions. (B) Immunoprecipitation (IP) experiments using COS1 lysates (20 mg of total protein per sample) transiently expressing enhanced green fluorescent protein (EGFP) as a control or human IQGAP1 or IQGAP2 (24 h posttransfection) were completed using protein G agarose-conjugated antibodies (5 µg per sample) directed against IQGAP1 or IQGAP2. Immunodetection was completed using the same antibodies. An immunoblot of corresponding lysates is shown to document protein expression. Note the high level of endogenous IQGAP1 expression in COS1 cells transfected with enhanced green fluorescent protein, with no evidence of IQGAP1-IQGAP2 complexes. Results represent one complete set of experiments reproduced on three different occasions.
|
Accordingly, we generated Iqgap1–/– Iqgap2–/– mice for more-detailed analyses, assessing the development of HCC as the primary end point (more-detailed characterization of these mice will be presented elsewhere). A lack of hepatic IQGAP1 and IQGAP2 expression was clearly evident by immunoblot analysis, with residual IQGAP1 and IQGAP2 expression in Iqgap1+/– Iqgap2+/– double heterozygotes (Fig. 7A). Progressive, age-dependent increases in hepatic AST levels in 18- to 24-month-old Iqgap2–/– mice were demonstrated (compare results in Fig. 7A to Fig. 2A results for 4- and 8-month-old mice), with normal levels found in Iqgap1–/– Iqgap2–/– mice of this age group (Fig. 7B). Kaplan-Meier survival curves for mice up to 24 months of age confirmed the progressive increase in the death rate of Iqgap2–/– mice compared to that of wild-type control mice (Fig. 7C). Statistically significant (P < 0.05) separation of these survival curves was first evident by 200 days after birth, with progressive divergence over time. Entirely consistent with the normalization of the hepatic enzyme defect, Iqgap1–/– Iqgap2–/– mice had survival durations that were essentially identical to those of wild-type controls and were clearly improved compared to those of Iqgap2–/– mice.
![]() View larger version (31K): [in a new window] |
FIG. 7. Results from comparative studies of Iqgap2–/– and Iqgap1–/– Iqgap2–/– mice. (A) Immunoblots of liver lysates (30 µg/lane) from age-matched (4-month-old) Iqgap1–/– Iqgap2–/– (double-knockout [DKO]), Iqgap1+/– Iqgap2+/– double-heterozygote (HET/HET), and wild-type (WT) mice were obtained using either anti-IQGAP1 or anti-IQGAP2 antibodies. Antibody against actin was used to document the loading of equal amounts of protein. (B) AST levels in sera from 18- to 24-month-old wild-type (n = 12), Iqgap2–/– (n = 14), and Iqgap1–/– Iqgap2–/– (n = 23) mice were determined; data are presented as the means ± SEM, and P values are indicated. (C) Aggregate Kaplan-Meier survival curves for wild-type, Iqgap2–/–, and Iqgap1–/– Iqgap2–/– mice are displayed, with cohort numbers in parentheses; intergroup Mantel-Cox analyses demonstrated highly significant survival-rate differences between Iqgap2–/– and either wild-type or Iqgap1–/– Iqgap2–/– mice (P = 0.002), with no difference in survival rates between wild-type and Iqgap1–/– Iqgap2–/– mice. (D) Incidence of HCC among wild-type, Iqgap2–/–, and Iqgap1–/–/Iqgap2–/– mice of different ages as established by liver histology (P values are shown). N/A, not applicable. (E) Liver weights as percentages of total body weights of wild-type mice (n = 18) and Iqgap2–/– (n = 10) and Iqgap1–/– Iqgap2–/– (n = 6) mice affected with HCC. The bar graph shows means ± SEM, and P values are displayed.
|
|
|
|---|
What is the relationship between IQGAP1 and IQGAP2 in HCC development? In normal hepatocytes, IQGAP2 is the predominant one of the two homologues, although IQGAP1 is reciprocally induced in Iqgap2–/– livers. This induction was readily evident by 16 weeks of age (preceding the onset of HCC) and continued throughout the lifetimes of the Iqgap2–/– mice. As importantly, our data on HCC development in Iqgap1–/– Iqgap2–/– mice suggest that maximal phenotypic penetrance is IQGAP1 dependent. Thus, although HCC did develop in Iqgap1–/– Iqgap2–/– mice, the incidence was considerably lower (29%) than the 86% incidence in Iqgap2–/– mice in the age group of 18 months and older. Furthermore, the overall aggressiveness of hepatic cancer in Iqgap1–/– Iqgap2–/– mice was diminished compared to that in Iqgap2–/– mice, as evidenced by smaller HCC tumors than those in Iqgap2–/– mice, coupled with cumulative survival rates that were indistinguishable from those of wild-type controls. Thus, despite the homology of IQGAP1 and IQGAP2, these collective observations suggest that these proteins retain functionally divergent (and nonredundant) roles in hepatocellular carcinogenesis. These data are consistent with results in previous reports demonstrating IQGAP1 overexpression in colon cancer (37), gastric cancer (44), and metastatic melanoma (11), although alterations of IQGAP2 expression were not reported previously. Notably, the knockout of murine IQGAP1 does not result in altered levels of IQGAP2 (30), although Iqgap1–/– mice displayed late-onset gastric hyperplasia. Progression to cancer was not evident, again reinforcing the functional divergence of these homologues.
Although IQGAP1 and IQGAP2 were collectively identified within the broader scaffolding complex comprising E-cadherin and β-catenin, there was no evidence that IQGAP1's modulatory effect on HCC development was mediated by direct interaction with IQGAP2. Immunoprecipitation experiments conducted with wild-type and null (Iqgap1–/– and Iqgap2–/–) hepatocytes confirmed the direct association of IQGAP2 with the β-catenin-E-cadherin complex and demonstrated this association to be unrelated to the presence of IQGAP1 (although there was a suggestion of IQGAP1-dependent functional binding cooperativity). Nonetheless, results from both hepatocyte and in vitro studies with COS1 cells gave no evidence for direct association between IQGAP1 and IQGAP2. Thus, despite evidence for the presence of IQGAP1 homodimers that may regulate protein function (3, 40), our data do not support the presence of direct IQGAP1-IQGAP2 interactions (i.e., heterodimers) that could modulate function via dominant negative effects. While these conclusions are based on results from studies completed with fasting animals, we cannot exclude the possibility that functionally dynamic changes within the scaffolding complex occur during times of altered hepatic metabolic states.
The overexpression of IQGAP1 was associated with acquired mutations in β-catenin, and the accumulation of dephosphorylated (active) β-catenin was specifically detected in HCC livers and not in livers from younger wild-type or Iqgap2–/– mice (without HCC). These data are consistent with previous observations that 26% of human HCCs and 50% of mouse HCCs have β-catenin-activating mutations, located predominantly in the potential GSK-3β phosphorylation site (15). Interestingly, IQGAP1 is known to display distinct effects on β-catenin function by inhibiting the ability of β-catenin to promote cell-cell adhesion (28). Furthermore, IQGAP1 overexpression in SW480 colon carcinoma cells stimulates the translocation of β-catenin to the nucleus, with a concomitant increase in transcriptional activity (6). Nonetheless, β-catenin overexpression appears to be insufficient for the development of HCC (9), suggesting that the coordinated overexpression and translocation of IQGAP1 and β-catenin may act in concert to promote carcinogenesis, primarily in the setting of IQGAP2 deficiency. Furthermore, it is intriguing that IQGAP1 has recently been identified as an RNA binding protein with the capacity to modulate gene expression (51), although whether isolated IQGAP1 overexpression is sufficient for HCC development remains unestablished.
Iqgap2–/– hepatocytes display an interesting structural defect in mitochondrial cristae occurring in concert with apoptosis and hepatic enzyme release. Neither the enzyme release nor the mitochondrial defects were evident in Iqgap1–/– Iqgap2–/– mice. Although cristae in Iqgap2–/– mice appeared to be shortened compared to those in wild-type mice (with vast portions of matrix devoid of cristae altogether), these structural defects were unassociated with mitochondrial genome integrity and mtPTP function (Fig. 2 and 3). Based on retained functional mitochondrial integrity, we hypothesize that the structural defects occur as phenomena secondary to an apoptotic stimulus in Iqgap2–/– hepatocytes. There is no evidence that IQGAP2 may be a structural component of hepatocyte mitochondria (4). Moreover, normal β-oxidation levels in Iqgap2–/– livers (our unpublished observations) indirectly confirm the absence of excessive reactive oxygen species formation (49), since the induction of the β-oxidation pathway is a significant source of reactive oxygen species. Thus, the structural defect in Iqgap2–/– mitochondria is unlikely to be causally implicated in HCC development but rather to be a secondary event. Of note, identical mitochondrial defects linked to apoptotic triggers have been observed in livers of mice transgenic for the hepatitis C virus core gene, with the subsequent development of HCC by 16 months of age (36).
Therapeutic options for the control of the Wnt/β-catenin signaling pathway are currently limited. One of the promising approaches is the employment of small molecule antagonists that reduce β-catenin interaction with its binding partners (further reviewed in references 5 and 29). Our studies using a mouse model offer two novel (but functionally opposing) candidate genes for targeted therapy of HCC. If our results are confirmed for humans, means of abolishing IQGAP1 or enhancing IQGAP2 function and/or critical interactions would represent logical approaches for targeted therapy of human HCC.
This work was supported by NIH grants DK62040 (V.A.S.) and HL49141 (W.F.B.).
Published ahead of print on 7 January 2008. ![]()
|
|
|---|

. Biochim. Biophys. Acta 1709:195-202.[Medline]This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»